The U.S. Food and Drug Administration (FDA) approved TG Therapeutics Inc's Briumvi – a monoclonal antibody for treating patients with relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal antibody approved for RMS that can be administered in a one-hour infusion following the first dose.
The approval by the FDA may help offset the headwind to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year. The approval was based on a late-stage study that suggested that the drug was effective in mitigating the annualized relapse rates in patients. It, however, comes with a caution of infusion reactions from the drug.
TG expects to launch Briumvi commercially in the U.S. in the first quarter of 2023.
TGTX broke above its upper Bollinger Band on April 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for TGTX moved out of overbought territory on May 12, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on May 16, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on TGTX as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on May 15, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 228 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (144.928) is normal, around the industry mean (24.876). P/E Ratio (0.000) is within average values for comparable stocks, (122.944). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.306). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (416.667) is also within normal values, averaging (304.562).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company
|ETFs / NAME||Price $||Chg $||Chg %|
|Tekla Life Sciences Investors|
|Roundhill Sports Betting & iGaming ETF|
|Dimensional Emerging Core Equity Mkt ETF|
|SmartETFs Asia Pcfc Dvdnd Bldr ETF|
|Global X Cannabis ETF|
A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with BEAM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then BEAM could also see price increases.
|BEAM - TGTX|
|SANA - TGTX|
|EDIT - TGTX|
|RCKT - TGTX|
|ADPT - TGTX|